{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/parvovirus-b19-infection/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"020d2cdb-0f7f-5bc0-a249-98fc3690b68c","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 1e887701-e892-46a8-bf8d-b3fd2d7c7d79 --><h2>Changes</h2><!-- end field 1e887701-e892-46a8-bf8d-b3fd2d7c7d79 -->","summary":null,"htmlStringContent":"<!-- begin item 65161ee3-6deb-4259-9609-45d8b75da4e6 --><!-- begin field 41e72170-10bf-4ec6-8017-ac1c74de1809 --><div><strong>January to February 2017</strong> — reviewed. A literature search was conducted in January 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The name of the topic has been changed to Parvovirus B19 infection (slapped cheek syndrome). The topic has undergone significant restructuring of the Scenarios. No major changes to recommendations have been made.</div><!-- end field 41e72170-10bf-4ec6-8017-ac1c74de1809 --><!-- end item 65161ee3-6deb-4259-9609-45d8b75da4e6 -->","topic":{"id":"a0e6adce-f85f-55b0-8d7f-3b5e75836d40","topicId":"3ea4cf87-3eee-4e3f-a6d0-b0ee3a4ee3ad","topicName":"Parvovirus B19 infection","slug":"parvovirus-b19-infection","lastRevised":"Last revised in February 2017","chapters":[{"id":"c45face5-dc30-586a-b7ca-3b24305bd068","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cc09231e-bb7a-5379-aeec-7c830288098e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2971cfc1-4839-5be6-b726-20b9383ae294","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"020d2cdb-0f7f-5bc0-a249-98fc3690b68c","slug":"changes","fullItemName":"Changes"},{"id":"af1bc49c-d614-521b-b6f3-ad084fc2aed9","slug":"update","fullItemName":"Update"}]},{"id":"7c9f0c10-cf1d-5723-856f-e0bc2d270210","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bb1635ce-433b-5f39-a93a-27b4488878c5","slug":"goals","fullItemName":"Goals"},{"id":"3c7eed51-287a-5bcb-8519-40ef7f5784aa","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"291f85a1-8911-59d4-82d6-62ce4daff1c0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e66b8854-eb00-59b9-85d9-f50343f36470","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ce817770-4fbe-5b47-b4ed-56b723012488","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"faa5c5db-5837-5cbd-8e56-78bc7ac42137","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0f0e8f26-e2c7-5de3-b012-e340b25ad622","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"afcf1b63-41ac-5295-91b5-4e19bc828249","slug":"definition","fullItemName":"Definition"},{"id":"60a93741-3863-58bb-8394-a33804062373","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1cfa61b6-71af-5e94-9e40-95b29e9f97dc","slug":"complications","fullItemName":"Complications"},{"id":"034c66fb-a99f-5a21-a031-d557dc647301","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"53019719-ec11-57d5-afd3-3ed2e9939168","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e7eca192-b219-5e71-8ecd-6d2e6cf0f3da","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"2b824d0f-b0b0-5801-8def-a38d172c2532","slug":"investigations","fullItemName":"Investigations"},{"id":"7daba43a-1410-5703-8a94-b6530a5dfccc","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b0275eae-f19c-57fb-834c-03df7c6dcea3","fullItemName":"Management","slug":"management","subChapters":[{"id":"73c2e9d4-b567-504f-9b28-36966a247590","slug":"children-adults-not-pregnant","fullItemName":"Scenario: Children and adults (not pregnant)"},{"id":"25b4fecb-ae9d-58f7-ad14-7ace595c0800","slug":"pregnant-women","fullItemName":"Scenario: Pregnant women"}]},{"id":"bdf3d270-5563-5eb4-804f-68fce2e7e7dd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"73875656-8429-5584-82e6-d06c0a5f52ea","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8dc117ba-c373-5ee0-a7aa-fc63a62a7067","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"24bd5691-28ce-53b1-be8b-f0e51e40db4b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6b35b969-66a8-5431-900a-a524f0bf1a89","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"63ad51a8-8325-52f2-a254-ed3ccae9f508","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"174a35a7-6fa3-58ef-9e06-6325d5f0111b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c6c0fc6f-31f8-5681-bbce-4ed5b6b16e4e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2971cfc1-4839-5be6-b726-20b9383ae294","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"dd64e2cc-7e3a-5a4d-9107-823fa3e70ec7","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 3c3bebcc-10cf-45fd-9eaa-36911cd7f487 --><h3>Previous changes</h3><!-- end field 3c3bebcc-10cf-45fd-9eaa-36911cd7f487 -->","summary":null,"htmlStringContent":"<!-- begin item bd879971-cc4a-45c0-abc9-305858c14684 --><!-- begin field f8daf538-19bb-4782-bafe-469d63280955 --><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>August 2012 </strong>— minor typographical error corrected.</p><p><strong>July 2011 </strong>— minor update. More exact paracetamol dosing for children has been introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) following publication of the document <em>Paracetamol: updated dosing for children to be introduced</em> (July 2011). Prescriptions have been updated to reflect the revised dosing. Issued in July 2011. </p><p><strong>January to April 2010 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field f8daf538-19bb-4782-bafe-469d63280955 --><!-- end item bd879971-cc4a-45c0-abc9-305858c14684 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}